page contents
  • Anne

Dec. 2020 News Update

Updated: Dec 15, 2020

The experimental drug Eganelisib (IPI-549) in combination with Atezolizumab (Tecentriq) and nab-Paclitaxel (Abraxane) appears highly encouraging for triple negative MBC patients:

Eganelisib is a targeted therapy that reprograms pro-tumor macrophages to relieve immune suppression and activate anti-tumor T-cells. Although the combination of Tecentriq and Abraxane has been FDA-approved as first-line therapy for TNBC MBC patients whose cancer is PD-L1 positive, there remains an unmet need to improve therapies for TNBC MBC patients irrespective of PD-L1 status. The MARIO3 Phase 2 study enrolled 60 TNBC patients, 50% of whom were PD-L1 negative. Study results were highly encouraging, with 100% of the 13 evaluable patients experiencing tumor shrinkage, irrespective of PD-L1 status. The Overall Response Rate (ORR) for these patients was 69%, and the FDA has granted Fast-Track designation to Eganelisib in combination with an immune checkpoint inhibitor and chemotherapy for the first-line treatment of TNBC MBC patients.

746 views0 comments